<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35180640</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-6844</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>181</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Epilepsy research</Title>
          <ISOAbbreviation>Epilepsy Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Changes in the use of antiseizure medications in children and adolescents in Norway, 2009-2018.</ArticleTitle>
        <Pagination>
          <StartPage>106872</StartPage>
          <MedlinePgn>106872</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eplepsyres.2022.106872</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0920-1211(22)00023-7</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The use of antiseizure medications (ASMs) in the pediatric population is poorly studied. The purpose of this study was to investigate changes in the use of ASMs in children and adolescents compared to adults, and to elucidate safety considerations of certain drugs.</AbstractText>
          <AbstractText Label="METHOD" NlmCategory="METHODS">In this population-based pharmacoepidemiological study we used the Norwegian Prescription Database (NorPD), 2009-2018. The use of ASMs is presented as 1-year prevalence per 1000: number of ASM users in a year * 1000 / number of inhabitants that year. Variables included predetermined 5-year age groups, gender, ASMs, diagnosis-specific reimbursement codes, user, and population numbers. Selected ASMs used for specific indications or subgroups included ethosuximide, sulthiame, rufinamide, stiripentol, and clobazam. Gender differences in the use of valproate was examined due to safety considerations in girls/women.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The total number of ASM users (all indications) for the age groups 0-19 and 20-59 years was 5807 and 47,481 respectively in 2009, and 5906 and 61,447 respectively in 2018. The 1-year prevalence for children/adolescents (0-19 years) using ASMs in epilepsy remained stable from 2008 to 2018, 4.3-4.2/1000 inhabitants, as compared to 8.2-7.6/1000 in adults (20-59 years). Valproate, lamotrigine, and levetiracetam were the three most used ASMs in epilepsy in children/adolescents, similar to adults. The selected ASMs were mainly used in children/ adolescents, accounting for 0.74/1000 in 2018 versus 0.17/1000 in adults. A significant increase was seen for sulthiame (8-fold), ethosuximide (4-fold), clobazam (3-fold), and stiripentol (2-fold). The use of ASMs in non-epilepsy indications was limited and stable (17% in 2018); mainly lamotrigine in psychiatry in adolescents (15-19 years). This finding was in contrast to extensive non-epilepsy use in adults (71% in 2018).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Changes in the use of ASMs in children/adolescents differ as compared to adults, most notably extensive and increasing use of selected ASMs and limited non-epilepsy. This is an important part of pharmacovigilance and patient safety evaluations.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Heger</LastName>
            <ForeName>Katrine</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Program for Pharmacy, Faculty of Health Sciences, Oslo Metropolitan University, Pilestredet 50, 0167 Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Skipsfjord</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Program for Pharmacy, Faculty of Health Sciences, Oslo Metropolitan University, Pilestredet 50, 0167 Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kiselev</LastName>
            <ForeName>Yury</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Program for Pharmacy, Faculty of Health Sciences, Oslo Metropolitan University, Pilestredet 50, 0167 Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burns</LastName>
            <ForeName>Margrete Larsen</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>Section for Clinical Pharmacology, The National Center for Epilepsy (SSE), Dept of Pharmacology, Oslo University Hospital, G.F. Henriksens vei 23, 1300 Sandvika, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aaberg</LastName>
            <ForeName>Kari M</ForeName>
            <Initials>KM</Initials>
            <AffiliationInfo>
              <Affiliation>The National Center for Epilepsy (SSE), Oslo University Hospital, G.F. Henriksens vei 23, 1300 Sandvika, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johannessen</LastName>
            <ForeName>Svein I</ForeName>
            <Initials>SI</Initials>
            <AffiliationInfo>
              <Affiliation>Section for Clinical Pharmacology, The National Center for Epilepsy (SSE), Dept of Pharmacology, Oslo University Hospital, G.F. Henriksens vei 23, 1300 Sandvika, Norway; The National Center for Epilepsy (SSE), Oslo University Hospital, G.F. Henriksens vei 23, 1300 Sandvika, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Skurtveit</LastName>
            <ForeName>Svetlana</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Dept of Mental Disorders, The Norwegian Institute of Public Health, P.O. Box 222, Skøyen, 0213 Oslo, Norway; Norwegian Centre for Addiction Research (SERAF), Institute of Clinical Medicine, University of Oslo, Kirkeveien 166, 0450 Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johannessen Landmark</LastName>
            <ForeName>Cecilie</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Program for Pharmacy, Faculty of Health Sciences, Oslo Metropolitan University, Pilestredet 50, 0167 Oslo, Norway; Section for Clinical Pharmacology, The National Center for Epilepsy (SSE), Dept of Pharmacology, Oslo University Hospital, G.F. Henriksens vei 23, 1300 Sandvika, Norway; The National Center for Epilepsy (SSE), Oslo University Hospital, G.F. Henriksens vei 23, 1300 Sandvika, Norway. Electronic address: cecilie.landmark@oslomet.no.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Epilepsy Res</MedlineTA>
        <NlmUniqueID>8703089</NlmUniqueID>
        <ISSNLinking>0920-1211</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>44YRR34555</RegistryNumber>
          <NameOfSubstance UI="D000077287">Levetiracetam</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>614OI1Z5WI</RegistryNumber>
          <NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>U3H27498KS</RegistryNumber>
          <NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000927" MajorTopicYN="Y">Anticonvulsants</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004827" MajorTopicYN="Y">Epilepsy</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077287" MajorTopicYN="N">Levetiracetam</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antiepileptic drugs</Keyword>
        <Keyword MajorTopicYN="N">Epilepsy</Keyword>
        <Keyword MajorTopicYN="N">The Norwegian Prescription Database (NorPD)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>20</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35180640</ArticleId>
        <ArticleId IdType="doi">10.1016/j.eplepsyres.2022.106872</ArticleId>
        <ArticleId IdType="pii">S0920-1211(22)00023-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
